Amgenvs.Biogen
AMGN vs BIIB · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 6.7× larger than Biogen by market cap; Biogen trades at the lower P/E (21.3 vs 25.1).
Side by side
| AMGN | BIIB | |
|---|---|---|
| Market cap | $196B | $29.3B |
| Price | $363.39 | $199.15 |
| Today | −0.1% | +0.1% |
| Return YTD | +11.0% | +13.2% |
| Return 1Y | +21.0% | +47.2% |
| P/E | 25.1 | 21.3 |
| P/S | 5.3 | 2.9 |
| P/B | 21.3 | 1.6 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →More comparisons in Biotech & innovation
See where AMGN and BIIB sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →